Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07053904 | Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors | enrolling by invitation | Phase 1 | 54 | PharmaEssentiaINDUSTRY | 1 | Jul 8, 2025 | clinicaltrials |
| NCT07050641 | Phase I/II Study of SCTB39-1 in Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 110 | Sinocelltech Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07049458 |
| Study of CHO-A04 in Advanced Solid Tumors |
| not yet recruiting |
| Phase 1 / Phase 2 |
| 62 |
| Cho Pharma Inc.INDUSTRY |
| 1 |
| Jul 3, 2025 |
| clinicaltrials |
| NCT07050459 | A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 220 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 3, 2025 | clinicaltrials |
| NCT06669117 | FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations | recruiting | Phase 1 / Phase 2 | 140 | Pierre Fabre MedicamentINDUSTRY | 9 | Jul 2, 2025 | clinicaltrials |
| NCT06410131 | Study in Patients With Advanced Solid Tumors to Evaluate the Safety of FTL008.16 | recruiting | Phase 1 | 68 | Sound Biopharmaceuticals Ltd.INDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06415487 | ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | recruiting | Phase 1 | 30 | Acepodia Biotech, Inc.INDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT07045454 | A Study of MHB118C Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 200 | Minghui Pharmaceutical (Hangzhou) LtdINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06163391 | A Study to Assess Safety and Efficacy of SOT201 in Patients With Advanced/Metastatic Cancer | recruiting | Phase 1 | 40 | SOTIO Biotech AGINDUSTRY | 5 | Jun 29, 2025 | clinicaltrials |
| NCT05354323 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | active not recruiting | Phase 1 | 6 | NEC OncoImmunity ASINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07030478 | A Study to Evaluate the Safety and Tolerability of EP0089 | not yet recruiting | Phase 1 / Phase 2 | 190 | Ellipses PharmaINDUSTRY | 0 | Jun 22, 2025 | clinicaltrials |
| NCT07016997 | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 70 | Chiome Bioscience Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 6 | Jun 11, 2025 | clinicaltrials |
| NCT06883149 | PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor | recruiting | Phase 1 | 25 | Chinese PLA General HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT02608385 | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | active not recruiting | Phase 1 | 117 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07004296 | A Study of HDM2005 in Patients With Advanced Solid Tumor | recruiting | Phase 1 | 72 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2025 | clinicaltrials |
| NCT06987500 | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | recruiting | Phase 1 / Phase 2 | 132 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06878612 | a Polyphenol Whole Tumor Cell Vaccine in Patients With Advanced Malignant Solid Tumors | recruiting | Phase 1 | 9 | Xingchen PengOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 156 | Corbus Pharmaceuticals Inc.INDUSTRY | 2 | Jun 3, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04706715 | LAG3 PET Imaging in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 41 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05518253 | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Weijia Fang, MDOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT06954077 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors | recruiting | Phase 1 | 45 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT06998173 | Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DAT-1604 in Advanced Solid Tumor | not yet recruiting | Phase 1 | 228 | Danatlas Pharmaceuticals Co., LtdINDUSTRY | 1 | May 31, 2025 | clinicaltrials |
| NCT04866641 | Safety and Tolerability Study for T-1201 Injection 100 mg Kit in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 40 | Taivex Therapeutics CorporationINDUSTRY | 1 | May 30, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT06991478 | SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites | not yet recruiting | Phase 1 / Phase 2 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06992687 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 30 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06958679 | Evaluation of SYS6005 in Patients With Advanced Malignant Tumor | recruiting | Phase 1 | 132 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06970132 | Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | not yet recruiting | Phase 1 / Phase 2 | 102 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971523 | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | recruiting | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06307925 | A Phase I Study to Evaluate the Safety, Pharmacokinetics and Antitumor Activity of HC010 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 122 | HC Biopharma Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06968572 | Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion | recruiting | Phase 1 | 245 | Haisco Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT06966583 | NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC(NMN) | not yet recruiting | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | May 12, 2025 | clinicaltrials |
| NCT06963398 | A Study of HS-10529 in KRAS G12D Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 520 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 0 | May 9, 2025 | clinicaltrials |
| NCT06963502 | A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 | 762 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2025 | clinicaltrials |
| NCT06304571 | A Study of HC006 in Subjects With Advanced Solid Tumors | recruiting | Phase 1 | 76 | HC Biopharma Inc.INDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05263960 | A Study of CM350 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | Keymed Biosciences Co.LtdINDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT06956261 | NW-301 TCR-T in Patients With Advanced Solid Tumor | not yet recruiting | Phase 1 | 44 | Peking UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT06955390 | Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 1 | May 2, 2025 | clinicaltrials |
| NCT06954558 | A Single-Arm, Open-Label, Phase I Study of GK01 for Advanced Solid Tumor(GUARDIAN) | recruiting | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06949761 | A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | not yet recruiting | Phase 1 / Phase 2 | 240 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 29, 2025 | clinicaltrials |
| NCT05167071 | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | active not recruiting | Phase 1 | 53 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06947226 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 188 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06907628 | A Trial of SHR-3792 Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 8, 2025source: clinicaltrials